Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping
Background: Approved treatments for colorectal cancer (CRC) patients pretreated with two lines of therapy are of limited efficacy. Anti-epidermal growth factor receptor (EGFR) re-challenge might represent an option in RAS wild-type tumours. This study aimed to evaluate the efficacy of anti-EGFR re-c...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | ESMO Gastrointestinal Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949819824000815 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344679726809088 |
|---|---|
| author | J. Sgouros A. Eliades K. Papadopoulou N. Korfiatis D. Papamichael E. Fountzilas E. Tsolaki A. Achilleos K. Tsangaras C. Loizides G. Oikonomopoulos T. Makatsoris E. Kypri M. Ioannides G. Koumbaris G. Fountzilas P.C. Patsalis G. Pentheroudakis |
| author_facet | J. Sgouros A. Eliades K. Papadopoulou N. Korfiatis D. Papamichael E. Fountzilas E. Tsolaki A. Achilleos K. Tsangaras C. Loizides G. Oikonomopoulos T. Makatsoris E. Kypri M. Ioannides G. Koumbaris G. Fountzilas P.C. Patsalis G. Pentheroudakis |
| author_sort | J. Sgouros |
| collection | DOAJ |
| description | Background: Approved treatments for colorectal cancer (CRC) patients pretreated with two lines of therapy are of limited efficacy. Anti-epidermal growth factor receptor (EGFR) re-challenge might represent an option in RAS wild-type tumours. This study aimed to evaluate the efficacy of anti-EGFR re-challenge strategies (panitumumab/chemotherapy). Materials and methods: RAS wild-type metastatic CRC patients following first-line chemotherapy + anti-EGFR agent and second-line chemotherapy ± anti-vascular endothelial growth factor agent were eligible. Panitumumab with irinotecan or oxaliplatin-based chemotherapy was used. The primary objective was response rate (RR). Secondary objectives were safety, progression-free survival and overall survival. Next-generation sequencing-based genotyping in archived tissue and plasma was carried out to identify prognostic factors. Results: The study closed prematurely, due to poor accrual, with 23 patients included. Most patients had primary tumours in the left colon/rectum, and the liver was the most common metastatic site. Treatment modifications were required in 74% of patients due to side-effects primarily, neutropenia and acneiform rash. One patient died from hepatic failure. The objective RR in the intention-to-treat population was 13%, and the disease control rate (DCR) was 52%. Forty-eight percent of patients tested via liquid biopsy had RAS mutations before re-challenge with panitumumab despite a median interval from previous anti-EGFR therapy of 12 months. Control of disease did not correlate with the results of liquid biopsy. RR and DCR in patients without RAS mutations in liquid biopsies were 18.2% and 54.5%, respectively. Conclusion: Panitumumab/chemotherapy as an anti-EGFR re-challenge strategy had modest activity in our patient cohort. |
| format | Article |
| id | doaj-art-b4985d13ea404b9daa8d42b705efa7ae |
| institution | Kabale University |
| issn | 2949-8198 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | ESMO Gastrointestinal Oncology |
| spelling | doaj-art-b4985d13ea404b9daa8d42b705efa7ae2025-08-20T03:42:37ZengElsevierESMO Gastrointestinal Oncology2949-81982025-03-01710012010.1016/j.esmogo.2024.100120Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotypingJ. Sgouros0A. Eliades1K. Papadopoulou2N. Korfiatis3D. Papamichael4E. Fountzilas5E. Tsolaki6A. Achilleos7K. Tsangaras8C. Loizides9G. Oikonomopoulos10T. Makatsoris11E. Kypri12M. Ioannides13G. Koumbaris14G. Fountzilas15P.C. Patsalis16G. Pentheroudakis17Department of Medical Oncology, Agii Anargiri Cancer Center and Genaral Hospital, Athens, Greece; Correspondence to: Dr Joseph Sgouros, Medical Oncology Department, Agii Anargiri Cancer Center and General Hospital, N.Kifisia, Athens, Greece 14564. Tel: +30-21-03-50-12-77Medicover Genetics, Nicosia, CyprusLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, GreeceDepartment of Informatics, Ionian University, Corfu, GreeceBank of Cyprus Oncology Center, Nicosia, CyprusDepartment of Medical Oncology, St Luke’s Clinic, Thessaloniki, Greece; European University Cyprus, Engomi, CyprusLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, GreeceMedicover Genetics, Nicosia, CyprusMedicover Genetics, Nicosia, Cyprus; Department of Life and Health Sciences, University of Nicosia, Nicosia, CyprusMedicover Genetics, Nicosia, CyprusSecond Department of Medical Oncology, Metropolitan Hospital, Piraeus, GreeceDivision of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, GreeceMedicover Genetics, Nicosia, CyprusMedicover Genetics, Nicosia, CyprusMedicover Genetics, Nicosia, CyprusAristotle University of Thessaloniki, Thessaloniki, GreeceMedicover Genetics, Nicosia, Cyprus; Department of Human Genetics, School of Medicine, University of Nicosia Medical School, Nicosia, CyprusDepartment of Medical Oncology, Medical School, University of Ioannina, Ioannina, GreeceBackground: Approved treatments for colorectal cancer (CRC) patients pretreated with two lines of therapy are of limited efficacy. Anti-epidermal growth factor receptor (EGFR) re-challenge might represent an option in RAS wild-type tumours. This study aimed to evaluate the efficacy of anti-EGFR re-challenge strategies (panitumumab/chemotherapy). Materials and methods: RAS wild-type metastatic CRC patients following first-line chemotherapy + anti-EGFR agent and second-line chemotherapy ± anti-vascular endothelial growth factor agent were eligible. Panitumumab with irinotecan or oxaliplatin-based chemotherapy was used. The primary objective was response rate (RR). Secondary objectives were safety, progression-free survival and overall survival. Next-generation sequencing-based genotyping in archived tissue and plasma was carried out to identify prognostic factors. Results: The study closed prematurely, due to poor accrual, with 23 patients included. Most patients had primary tumours in the left colon/rectum, and the liver was the most common metastatic site. Treatment modifications were required in 74% of patients due to side-effects primarily, neutropenia and acneiform rash. One patient died from hepatic failure. The objective RR in the intention-to-treat population was 13%, and the disease control rate (DCR) was 52%. Forty-eight percent of patients tested via liquid biopsy had RAS mutations before re-challenge with panitumumab despite a median interval from previous anti-EGFR therapy of 12 months. Control of disease did not correlate with the results of liquid biopsy. RR and DCR in patients without RAS mutations in liquid biopsies were 18.2% and 54.5%, respectively. Conclusion: Panitumumab/chemotherapy as an anti-EGFR re-challenge strategy had modest activity in our patient cohort.http://www.sciencedirect.com/science/article/pii/S2949819824000815colorectal cancerRAS wild typeanti-EGFR re-challengepanitumumab |
| spellingShingle | J. Sgouros A. Eliades K. Papadopoulou N. Korfiatis D. Papamichael E. Fountzilas E. Tsolaki A. Achilleos K. Tsangaras C. Loizides G. Oikonomopoulos T. Makatsoris E. Kypri M. Ioannides G. Koumbaris G. Fountzilas P.C. Patsalis G. Pentheroudakis Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping ESMO Gastrointestinal Oncology colorectal cancer RAS wild type anti-EGFR re-challenge panitumumab |
| title | Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping |
| title_full | Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping |
| title_fullStr | Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping |
| title_full_unstemmed | Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping |
| title_short | Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping |
| title_sort | anti egfr re challenge with chemotherapy in ras wild type advanced colorectal cancer a repeat study efficacy and correlations with tissue and plasma genotyping |
| topic | colorectal cancer RAS wild type anti-EGFR re-challenge panitumumab |
| url | http://www.sciencedirect.com/science/article/pii/S2949819824000815 |
| work_keys_str_mv | AT jsgouros antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT aeliades antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT kpapadopoulou antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT nkorfiatis antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT dpapamichael antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT efountzilas antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT etsolaki antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT aachilleos antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT ktsangaras antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT cloizides antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT goikonomopoulos antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT tmakatsoris antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT ekypri antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT mioannides antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT gkoumbaris antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT gfountzilas antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT pcpatsalis antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping AT gpentheroudakis antiegfrrechallengewithchemotherapyinraswildtypeadvancedcolorectalcancerarepeatstudyefficacyandcorrelationswithtissueandplasmagenotyping |